TouchRESPIRATORY got the opportunity to catch up with Dr Sarah Diver (University of Leicester, Leicester, UK) around the CASCADE study, investigating the use of tezepelumab in patients with moderate-to-severe uncontrolled asthma.
‘Effect of tezepelumab on airway inflammatory cells, remodeling and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma: a randomized, double-blind, placebo-controlled trial’ was presented at ATS 2021 International Conference, 14-19 May, 2021.
Questions
- What are the limitations of current biologic therapies for asthma? (0:18)
- What makes tezepelumab unique among biologic treatments for moderate-to severe asthma? (2:23)
- What have the NAVIGATOR and SOURCE studies taught us about the efficacy and safety of tezepelumab in this treatment setting? (3:45)
- What are the aims and design of the CASCADE study? (5:37)
- What are the primary and secondary outcome measures of this study and how well were these achieved? (7:38)
Disclosures: Sarah Diver has nothing to disclose in relation to this video.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ATS 2021 (Virtual).
